Biotechnology giant Regeneron Pharmaceuticals has emerged as the successful bidder in the bankruptcy auction for genetic testing pioneer 23andMe, offering $256 million for the majority of the company’s assets. Announced Monday, the deal would transfer 23andMe’s consumer genomics business and valuable biobank containing genetic data from millions of customers to Regeneron, pending bankruptcy court and […]
The post Regeneron to Buy 23andMe for $256M Amid Growing Data Privacy Concerns appeared first on GBHackers Security | #1 Globally Trusted Cyber Security News Platform.